Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Promising survival and disease control in third-line or greater metastatic or locally advanced pancreatic cancer patients following chemo-radiation and novel combination of aldoxorubicin, N-803 IL-15 superagonist, and PDL1- NK cell therapy.
Authors
Tara Elisabeth Seery
Hoag Cancer Center, Newport Beach, CA
Tara Elisabeth Seery , Chaitali Singh Nangia , Heidi Ann McKean , Leonard S. Sender , Paul Bhar , Sandeep K. Reddy , Patrick Soon-Shiong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04390399
DOI
10.1200/JCO.2022.40.4_suppl.582
Abstract #
582
Poster Bd #
J10
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Overall survival in patients with metastatic or locally advanced pancreatic cancer following chemoradiation with novel combination of aldoxorubicin, N-803 IL-15 superagonist, and PDL1- NK cell therapy.
First Author: Tara Elisabeth Seery
Poster
2021 ASCO Annual Meeting
A phase 2 study of cyclophosphamide (CY), GVAX, pembrolizumab (Pembro), and stereotactic body radiation (SBRT) in patients (pts) with locally advanced pancreas cancer (LAPC).
First Author: Valerie Lee
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Metronomic oral cyclophosphamide as maintenance therapy in metastatic pancreatic ductal adenocarcinoma.
First Author: Michele Reni
Poster
2022 ASCO Annual Meeting
Phase 2 Quilt 88 trial of DAMP inducers combined with IL15 superagonist, N-803, and anti–PD-L1 NK cell therapy more than doubles historical overall survival in patients with third- to sixth-line advanced pancreatic cancer.
First Author: Tara Elisabeth Seery